Search Results
Search for other papers by SS Guo in
Google Scholar
PubMed
Search for other papers by X Wu in
Google Scholar
PubMed
Search for other papers by AT Shimoide in
Google Scholar
PubMed
Search for other papers by J Wong in
Google Scholar
PubMed
Search for other papers by F Moatamed in
Google Scholar
PubMed
Search for other papers by MP Sawicki in
Google Scholar
PubMed
Pancreatic endocrine tumours (PETs) occur sporadically or are inherited as part of the multiple endocrine neoplasia type-1 syndrome. Little is known about the molecular events leading to these tumours. Cyclin D1, a key regulator of the G1/S transition of the cell cycle, is overexpressed in a variety of human cancers as well as certain endocrine tumours. We hypothesized that similar to other endocrine tumours, cyclin D1 is overexpressed in human sporadic PETs. Cyclin D1 protein overexpression was found in 20 of 31 PETs (65%) when compared with normal pancreatic tIssue. Furthermore, Northern blot analysis suggests that cyclin D1 up-regulation occurs at the post-transcriptional level in some PETs. Because the key cell growth signalling pathways p42/p44/ERK (extracellular signal-regulated kinase), p38/MAPK (mitogen-activated protein kinase), and Akt/PKB (protein kinase B) can regulate cyclin D1 protein expression in other cell types, pancreatic endocrine tumours were analysed with phospho-specific antibodies against the active forms of these proteins to elucidate a tIssue-specific regulatory mechanism of cyclin D1 in PETs. We found frequent activation of the p38/MAPK and Akt pathways, but down-regulation of the ERK pathway, in cyclin D1 overexpressing PETs. This study demonstrates that cyclin D1 overexpression is associated with human sporadic PET tumorigenesis, and suggests that this up-regulation may occur at the post-transcriptional level. These findings will direct future studies of PETs towards cell cycle dysregulation and the identification of key growth factor pathways involved in the formation of these tumours.
Search for other papers by J Doi in
Google Scholar
PubMed
Search for other papers by H Takemori in
Google Scholar
PubMed
Search for other papers by M Ohta in
Google Scholar
PubMed
Search for other papers by Y Nonaka in
Google Scholar
PubMed
Search for other papers by M Okamoto in
Google Scholar
PubMed
Epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) are pluripotent growth factors that stimulate both the proliferation and steroidogenesis of adrenocortical cells. Here we demonstrate that EGF and bFGF specifically induce mRNA of 3beta-hydroxysteroid dehydrogenase type II (3betaHSD II) and suppress that of 17alpha-hydroxylase/lyase P450 (CYP17) in human adrenocortical H295R cells. The induction of 3betaHSD II mRNA did not occur until 6 h after the growth factor treatment and was completely abolished in the presence of a protein synthesis inhibitor, cycloheximide (CHX), suggesting that the induction required de novo protein synthesis. The CYP17 mRNA suppression began at almost the same time as the induction of the 3betaHSD II mRNA. Interestingly, the CYP17 mRNA level was increased by the CHX treatment. Both the 3betaHSD II and CYP17 mRNAs were repressed by treatment with a calmodulin kinase II (CaMK II) inhibitor, KN-93, and were enhanced by a mitogen-activated protein kinase (MAPK) inhibitor, PD98059. The PD98059-mediated induction of the 3betaHSD II mRNA was completely blocked by the CHX treatment. Interestingly, treatment with EGF in the presence of both PD98059 and CHX produced a greater increase in the CYP17 mRNA than did treatment in the presence of PD98059 alone. These results suggest that CHX-sensitive factor(s) and CaMK II- and MAPK-signaling pathways may have important roles in both induction of 3betaHSD II and suppression of CYP17 by EGF or bFGF in H295R cells.
Search for other papers by A Acitores in
Google Scholar
PubMed
Search for other papers by N Gonzalez in
Google Scholar
PubMed
Search for other papers by V Sancho in
Google Scholar
PubMed
Search for other papers by I Valverde in
Google Scholar
PubMed
Search for other papers by ML Villanueva-Penacarrillo in
Google Scholar
PubMed
Glucagon-like peptide-1 (GLP-1), an incretin with glucose-dependent insulinotropic and insulin-independent antidiabetic properties, has insulin-like effects on glucose metabolism in extrapancreatic tissues participating in overall glucose homeostasis. These effects are exerted through specific receptors not associated with cAMP, an inositol phosphoglycan being a possible second messenger. In rat hepatocytes, activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB), protein kinase C (PKC) and protein phosphatase 1 (PP-1) has been shown to be involved in the GLP-1-induced stimulation of glycogen synthase. We have investigated the role of enzymes known or suggested to mediate the actions of insulin in the GLP-1-induced increase in glycogen synthase a activity in rat skeletal muscle strips. We first explored the effect of GLP-1, compared with that of insulin, on the activation of PI3K, PKB, p70s6 kinase (p70s6k) and p44/42 mitogen-activated protein kinases (MAPKs) and the action of specific inhibitors of these kinases on the insulin- and GLP-1-induced increment in glycogen synthase a activity. The study showed that GLP-1, like insulin, activated PI3K/PKB, p70s6k and p44/42. Wortmannin (a PI3K inhibitor) reduced the stimulatory action of insulin on glycogen synthase a activity and blocked that of GLP-1, rapamycin (a 70s6k inhibitor) did not affect the action of GLP-1 but abolished that of insulin, PD98059 (MAPK inhibitor) was ineffective on insulin but blocked the action of GLP-1, okadaic acid (a PP-2A inhibitor) and tumour necrosis factor-alpha (a PP-1 inhibitor) were both ineffective on GLP-1 but abolished the action of insulin, and Ro 31-8220 (an inhibitor of some PKC isoforms) reduced the effect of GLP-1 while completely preventing that of insulin. It was concluded that activation of PI3K/PKB and MAPKs is required for the GLP-1-induced increment in glycogen synthase a activity, while PKC, although apparently participating, does not seem to play an essential role; unlike in insulin signaling, p70s6k, PP-1 and PP-2A do not seem to be needed in the action of GLP-1 upon glycogen synthase a activity in rat muscle.
Search for other papers by SB Meroni in
Google Scholar
PubMed
Search for other papers by MF Riera in
Google Scholar
PubMed
Search for other papers by EH Pellizzari in
Google Scholar
PubMed
Search for other papers by MN Galardo in
Google Scholar
PubMed
Search for other papers by SB Cigorraga in
Google Scholar
PubMed
The gonadotropin FSH plays a key role in the control of Sertoli cell function. The FSH molecular mechanism of action is best recognized for its stimulation of the adenylyl cyclase/cAMP pathway. However, other signaling events have also been demonstrated in Sertoli cells. We have recently presented evidence that FSH can stimulate the phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB) pathway in 20-day-old Sertoli cells. At the same time, it was proposed that in 8-day-old Sertoli cells the effects of FSH on phosphorylated PKB (P-PKB) levels can be explained by a combination of increased secretion of endogenous IGF-I, decreased IGF-binding protein-3 (IGFBP-3) production, and a synergistic action of FSH on IGF-I-dependent PI3K activation. The aim of the present study was to determine whether the effect of FSH on 20-day-old Sertoli cells is mediated by IGF-I secretion. Twenty-day-old rat Sertoli cell cultures were used. FSH stimulation produced a time-dependent increment in P-PKB levels reaching maximal values in 60-min incubations. IGF-I stimulation was also time-dependent reaching maximal values in 15-min incubations. On the other hand, stimulation of the cultures with FSH showed time-dependent inhibition in phosphorylated mitogen-activated protein kinase (P-MAPK) levels. In sharp contrast, stimulation of the cultures with IGF-I showed time-dependent increments in P-MAPK levels reaching maximal stimulus in 15-min incubations. In order to rule out an IGF-I action on FSH stimulation of P-PKB levels, the effect of a specific IGF-I antibody on the ability of both hormones to increase P-PKB levels was evaluated. As expected, the antibody inhibited IGF-I stimulation of P-PKB levels. However, simultaneous addition of an IGF-I antibody with FSH did not modify the ability of the hormone to increase P-PKB levels. The next set of experiments intended to analyze the relevance of a PI3K/PKB pathway to two biological responses of Sertoli cells to FSH and IGF-I. The PI3K inhibitor, wortmannin, dose-dependently decreased FSH-stimulated lactate and transferrin production. On the other hand, wortmannin was not able to modify the ability of IGF-I to stimulate these metabolic events. In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels. In summary, results obtained so far support the hypothesis that FSH action on P-PKB levels and Sertoli cell metabolism in 20-day-old animals is not mediated by autocrine regulation of an IGF-I/ IGFBP-3 axis as previously proposed in 8-day-old Sertoli cells.
Search for other papers by CA McArdle in
Google Scholar
PubMed
Search for other papers by J Franklin in
Google Scholar
PubMed
Search for other papers by L Green in
Google Scholar
PubMed
Search for other papers by JN Hislop in
Google Scholar
PubMed
Sustained stimulation of G-protein-coupled receptors (GPCRs) typically causes receptor desensitisation, which is mediated by phosphorylation, often within the C-terminal tail of the receptor. The consequent binding of beta-arrestin not only prevents the receptor from activating its G protein (causing desensitisation), but can also target it for internalisation via clathrin-coated vesicles and can mediate signalling to proteins regulating endocytosis and mitogen-activated protein kinase (MAPK) cascades. GnRH acts via phospholipase C (PLC)-coupled GPCRs on pituitary gonadotrophs to stimulate a Ca(2+)-mediated increase in gonadotrophin secretion. The type I GnRH receptors (GnRH-Rs), found only in mammals, are unique in that they lack C-terminal tails and apparently do not undergo agonist-induced phosphorylation or bind beta-arrestin; they are therefore resistant to receptor desensitisation and internalise slowly. In contrast, the type II GnRH-Rs, found in numerous vertebrates, possess such tails and show rapid desensitisation and internalisation, with concomitant receptor phosphorylation (within the C-terminal tails) or binding of beta-arrestin, or both. The association with beta-arrestin may also be important for regulation of dynamin, a GTPase that controls separation of endosomes from the plasma membrane. Using recombinant adenovirus to express GnRH-Rs in Hela cells conditionally expressing a dominant negative mutant of dynamin (K44A), we have found that blockade of dynamin-dependent endocytosis inhibits internalisation of type II (xenopus) GnRH-Rs but not type I (human) GnRH-Rs. In these cells, blockade of dynamin-dependent internalisation also inhibited GnRH-R-mediated MAPK activation, but this effect was not receptor specific and therefore not dependent upon dynamin-regulated GnRH-R internalisation. Although type I GnRH-Rs do not desensitise, sustained activation of GnRH-Rs causes desensitisation of gonadotrophin secretion, and we have found that GnRH can cause down-regulation of inositol (1,4,5) trisphosphate receptors and desensitisation of Ca(2+) mobilisation in pituitary cells. The atypical resistance of the GnRH-R to desensitisation may underlie its atypical efficiency at provoking this downstream adaptive response. GnRH-Rs are also expressed in several extrapituitary sites, and these may mediate direct inhibition of proliferation of hormone-dependent cancer cells. Infection with type I GnRH-R-expressing adenovirus facilitated expression of high-affinity, PLC-coupled GnRH-R in mammary and prostate cancer cells, and these mediated pronounced antiproliferative effects of receptor agonists. No such effect was seen in cells transfected with a type II GnRH-R, implying that it is mediated most efficiently by a non-desensitising receptor. Thus it appears that the mammalian GnRH-Rs have undergone a period of rapidly accelerated molecular evolution that is of functional relevance to GnRH-Rs in pituitary and extrapituitary sites.
Search for other papers by Rhone A Mendoza in
Google Scholar
PubMed
Search for other papers by Emily E Moody in
Google Scholar
PubMed
Search for other papers by Marlene I Enriquez in
Google Scholar
PubMed
Search for other papers by Sylvia M Mejia in
Google Scholar
PubMed
Search for other papers by Gudmundur Thordarson in
Google Scholar
PubMed
et al . 2011 ). How the two ERs are causing phosphorylation of the p38 MAPK with opposite effects on cell growth is not understood. However, it is worth noting that p38 MAPK activation can be achieved through different signaling pathways ( Ge et al
Search for other papers by Ana Carolina Ronda in
Google Scholar
PubMed
Search for other papers by Andrea Vasconsuelo in
Google Scholar
PubMed
Search for other papers by Ricardo Boland in
Google Scholar
PubMed
. Nevertheless, the molecular mechanisms by which the hormone exerts antiapoptotic action in skeletal muscle cells are still poorly understood. The mitogen-activated protein kinases (MAPKs) are an evolutionary conserved family of intracellular signaling molecules
Search for other papers by Emily G Farrow in
Google Scholar
PubMed
Search for other papers by Lelia J Summers in
Google Scholar
PubMed
Search for other papers by Susan C Schiavi in
Google Scholar
PubMed
Search for other papers by James A McCormick in
Google Scholar
PubMed
Search for other papers by David H Ellison in
Google Scholar
PubMed
Search for other papers by Kenneth E White in
Google Scholar
PubMed
each primary antibody set. Quantitative RT-PCR Kidneys were harvested for RNA using TRIzol (Invitrogen) according to the manufacturer's protocol. RNA was harvested from the cellular lysates using the RNeasy kit (Qiagen, Inc.). MAPK signal (PAMM-061) and
Search for other papers by Tusty-Jiuan Hsieh in
Google Scholar
PubMed
Search for other papers by Pierre Fustier in
Google Scholar
PubMed
Search for other papers by Chih-Chang Wei in
Google Scholar
PubMed
Search for other papers by Shao-Ling Zhang in
Google Scholar
PubMed
Search for other papers by Janos G Filep in
Google Scholar
PubMed
Search for other papers by Shiow-Shiu Tang in
Google Scholar
PubMed
Search for other papers by Julie R Ingelfinger in
Google Scholar
PubMed
Search for other papers by I George Fantus in
Google Scholar
PubMed
Search for other papers by Pavel Hamet in
Google Scholar
PubMed
Search for other papers by John S D Chan in
Google Scholar
PubMed
M) (Fig. 8C ) or glucosamine (1 × 10 −6 M) (Fig. 8D ). These data demonstrate that prolonged incubation with Ang II, PKC or HBP activator impairs the effect of insulin signalling on p44/42 MAPK activation in IRPTCs. Effect
Department of Surgery and
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43212, USA
Search for other papers by Zhen-Yue Tong in
Google Scholar
PubMed
Department of Surgery and
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43212, USA
Search for other papers by David R Brigstock in
Google Scholar
PubMed
activated protein kinase (MAPK) in response to treatment with 0–100 ng/ml CCN2 3 for up to 5 h was assessed by Western blot of cell lysates using anti-phospho p42/p44 MAPK antibody (Cell Signaling Inc., Beverly, MA, USA) as compared with the total MAPK
